<DOC>
	<DOCNO>NCT00803101</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerance Beriplex® P/N ( Kcentra ) compare plasma regard rapid reversal coagulopathy induce vitamin K antagonists subject require immediate correction international normalize ratio ( INR ) emergency surgery .</brief_summary>
	<brief_title>An Open-label , Randomized , Multicenter Phase IIIb Study Assess Efficacy , Safety Tolerance BERIPLEX® P/N ( Kcentra ) Compared With Plasma Rapid Reversal Coagulopathy Induced Vitamin K Antagonists Subjects Requiring Urgent Surgical Procedure</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<mesh_term>Protein S</mesh_term>
	<criteria>Male female subject great equal 18 year , Subjects currently oral vitamin K antagonist ( VKA ) therapy , An urgent surgical procedure require within 24 hour start investigational medicinal product ( IMP ) , Due nature procedure , withdrawal oral VKA therapy infusion plasma also indicate reverse VKA effect , INR great equal 2 within 3 hour start IMP , Informed consent obtain . Subjects require urgent surgical procedure accord surgeon 's clinical judgment , accurate estimate blood loss possible ( e.g. , ruptured aneurysm ) , Subjects administration intravenous vitamin K vitamin K antagonists withdrawal alone adequately correct subject 's coagulopathy initiation urgent surgical procedure , Administration intravenous vitamin K 3 hour administration oral vitamin K 6 hour prior infusion IMP , Subjects lower INR within normal range may present unacceptable risk thromboembolic complication INR goal lower normalize INR risk procedureassociated stroke , Subjects , despite medical management include close monitoring diuretic , may , investigator assessment , tolerate total volume IMP require protocol , Expected need additional nonstudy blood product infusion IMP ( Note : Administration pack red blood cell exclusion criterion ) , Expected need platelet transfusion desmopressin Day 10 , Acute trauma reversal vitamin K antagonists alone would expect control resolve acute bleed complication and/or control acute bleeding event , Unfractionated low molecular weight heparin use within 24 hour randomization potential need completion procedure , History thromboembolic event , myocardial infarction , unstable angina pectoris , critical aortic stenosis , cerebral vascular accident , transient ischemic attack , severe peripheral vascular disease , disseminate intravascular coagulation within 3 month enrollment , Reversal VKA therapy alone may resolve coagulopathy ( eg , receive potent antiplatelet agent , i.e. , clopidogrel prasugrel , advance liver disease ) , Known history antiphospholipid antibody syndrome lupus anticoagulant antibody , Suspected confirm serious viral bacterial infection , e.g. , meningitis , sepsis time enrollment , Administration whole blood , plasma , plasma fraction platelet within 2 week prior inclusion study ( Note : Administration pack red blood cell exclusion criterion ) , Preexisting progressive fatal disease life expectancy le 2 month , Known inhibitor coagulation factor II , VII , IX , X ; hereditary protein C protein S deficiency ; heparininduced , type II thrombocytopenia , Treatment investigational medicinal product within 30 day prior inclusion study , Presence history hypersensitivity component study medication , Pregnant breastfeed woman , Prior inclusion study CSL Behring sponsor Beriplex study , For subject intracranial hemorrhage : Glasgow Coma Score &lt; 10 ( see Appendix 8 ) Modified Rankin Score &gt; 3 prior ICH ( see Appendix 9 ) Intracerebral hemorrhage Epidural hematomas Infratentorial hemorrhage Subarachnoid hemorrhage ( SAH ) subject Hunt Hess Scale &gt; 2 Subdural hematoma : judge acute subdural hematoma ( base neurosurgeon review ) concurrent SAH parenchymal contusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Anticoagulant reversal</keyword>
	<keyword>Prothrombin Complex Concentrate</keyword>
	<keyword>Coagulopathy</keyword>
	<keyword>Coumarin derivative</keyword>
	<keyword>Emergency surgery</keyword>
	<keyword>Invasive procedure</keyword>
	<keyword>Vitamin K</keyword>
	<keyword>Reversal coagulopathy induce coumarin derivative</keyword>
	<keyword>Kcentra</keyword>
</DOC>